The Journal of Immunology, Vol 155, Issue 9 4382-4390, Copyright © 1995 by American Association of Immunologists

ARTICLES

Nitric oxide synthesis contributes to IL-2-induced antitumor responses against intraperitoneal Meth A tumor

CY Yim, JR McGregor, OD Kwon, NR Bastian, M Rees, M Mori, JB Hibbs Jr and WE Samlowski
Department of Internal Medicine (Hematology/Oncology), Chonbuk National University Medical School, Korea.

IL-2 therapy is a potent inductive stimulus for nitric oxide (NO.) synthesis in mice and humans. It is not yet clear whether NO. can contribute to IL-2-induced therapeutic responses. The murine skin cancer Meth A is relatively resistant to lymphokine-activated killer (LAK) cell killing, allowing evaluation of the role of IL-2-induced NO. synthesis in vivo, without contribution by LAK cells. Subcutaneous IL-2 treatment of mice bearing i.p. Meth A tumor increased nitrite production by cells derived from ascites (63 +/- 14 microM vs 3.2 +/- 1.5 microM in untreated controls). N omega-monomethyl-L-arginine (MLA), NO. synthase inhibitor, prevented this increase. NO. production correlated in an inverse fashion with tumor cell proliferation in vitro. Evidence for IL-2-induced heme nitrosylation was demonstrated in tumor cells by electron paramagnetic resonance spectroscopy. By immunomagnetic depletion experiments, macrophages were implicated as a major source of NO. synthesis. Cytologic and flow-cytometric evaluation revealed that IL-2 treatment resulted in enhanced lymphocyte and macrophage recruitment into malignant ascites, and decreases in tumor cell recovery. MLA administration further increased host cell recovery. Subcutaneous IL-2 therapy increased urinary nitrate excretion up to eightfold in mice, and appeared to produce a significant survival advantage that was prevented by MLA administration.

This article has been cited by other articles:

				S. Kotamraju, C. L. Willams, and B. Kalyanaraman Statin-Induced Breast Cancer Cell Death: Role of Inducible Nitric Oxide and Arginase-Dependent Pathways Cancer Res., August 1, 2007; 67(15): 7386 - 7394. [Abstract] [Full Text] [PDF]

				M. Ferlito, K. Irani, N. Faraday, and C. J. Lowenstein Nitric oxide inhibits exocytosis of cytolytic granules from lymphokine-activated killer cells PNAS, August 1, 2006; 103(31): 11689 - 11694. [Abstract] [Full Text] [PDF]

				K. Kawakami, M. Kawakami, and R. K. Puri Nitric Oxide Accelerates Interleukin-13 Cytotoxin-Mediated Regression in Head and Neck Cancer Animal Model Clin. Cancer Res., August 1, 2004; 10(15): 5264 - 5270. [Abstract] [Full Text] [PDF]

				B. Pelaez, J. A. Campillo, J. A. Lopez-Asenjo, and J. L. Subiza Cyclophosphamide Induces the Development of Early Myeloid Cells Suppressing Tumor Cell Growth by a Nitric Oxide-Dependent Mechanism J. Immunol., June 1, 2001; 166(11): 6608 - 6615. [Abstract] [Full Text] [PDF]

				D. S. Tendler, C. Bao, T. Wang, E. L. Huang, E. A. Ratovitski, D. A. Pardoll, and C. J. Lowenstein Intersection of Interferon and Hypoxia Signal Transduction Pathways in Nitric Oxide-induced Tumor Apoptosis Cancer Res., May 1, 2001; 61(9): 3682 - 3688. [Abstract] [Full Text]

				M. G. Cifone, S. D'Alo, R. Parroni, D. Millimaggi, L. Biordi, S. Martinotti, and A. Santoni Interleukin-2-Activated Rat Natural Killer Cells Express Inducible Nitric Oxide Synthase That Contributes to Cytotoxic Function and Interferon-gamma Production Blood, June 1, 1999; 93(11): 3876 - 3884. [Abstract] [Full Text] [PDF]

				K. Hung, R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky The Central Role of CD4+ T Cells in the Antitumor Immune Response J. Exp. Med., December 21, 1998; 188(12): 2357 - 2368. [Abstract] [Full Text] [PDF]

				Y.-Q. Chen, J. H. Fisher, and M.-H. Wang Activation of the RON Receptor Tyrosine Kinase Inhibits Inducible Nitric Oxide Synthase (iNOS) Expression by Murine Peritoneal Exudate Macrophages: Phosphatidylinositol-3 Kinase Is Required for RON-Mediated Inhibition of iNOS Expression J. Immunol., November 1, 1998; 161(9): 4950 - 4959. [Abstract] [Full Text] [PDF]